| Renal Cell Carcinoma |
1 |
1 |
| Hepatocellular Carcinoma |
0 |
0.91 |
| Metastasis |
0 |
0.75 |
| Biologic Therapy |
0 |
0.65 |
| Cancer |
0 |
0.62 |
| Clinical Guidelines |
0 |
0.99 |
| Kidney Cancer |
0 |
0.45 |
| Liver Metastases |
0 |
0.42 |
| Renal Disease |
0 |
0.32 |
| Kidney |
0 |
0.31 |
| Targeted Cancer Therapy |
0 |
0.25 |
| Bone |
0 |
0.21 |
| Brain |
0 |
0.21 |
| Tumor |
0 |
0.21 |
| Histology of Bone |
0 |
0.18 |
| Interleukin-2 |
0 |
0.15 |
| Tyrosine Kinase Inhibitor |
0 |
0.15 |
| Patient Safety |
0 |
0.13 |
| Social Determinants of Health |
0 |
0.13 |
| Adverse Effects |
0 |
0.1 |
| Board Certification |
0 |
0.1 |
| Histology |
0 |
0.1 |
| Interleukin |
0 |
0.1 |
| Liver |
0 |
0.1 |
| Socioeconomics |
0 |
0.1 |
| Tissue |
0 |
0.1 |
| Tyrosine Kinase |
0 |
0.1 |
| Vascular Endothelial Growth Factor |
0 |
0.1 |